This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (12)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

Catherine Kim, MD, MPH; Keith W. Seidel, MD; Elizabeth A. Begier, MD; Yeong S. Kwok, MD

Arch Intern Med. 2001;161:1766-1771.

Background  Depot medroxyprogesterone acetate contraception is widely used in Navajo women, a high-risk population for diabetes mellitus. However, depot medroxyprogesterone may lead to weight gain and independently decrease insulin sensitivity. We studied the association between depot medroxyprogesterone and development of diabetes in Navajo women.

Methods  We studied Navajo women aged 18 to 50 years who had seen a health care provider at a Navajo Area Indian Health Service clinic at least once in 1998. Diabetic cases (n = 284) and nondiabetic controls (n = 570) were matched by age. Medical records were reviewed to determine contraception use before the diagnosis date of diabetes.

Results  Users of depot medroxyprogesterone were more likely to develop diabetes than patients who had used combination estrogen-progestin oral contraception only (odds ratio [OR], 3.8; 95% confidence interval [CI], 1.8-7.9). The excess risk persisted after adjustment for body mass index (OR, 3.6; 95% CI, 1.6-7.9). Longer use was associated with greater risk of diabetes. Users of depot medroxyprogesterone were also more likely to develop diabetes than patients who had never used hormonal contraception, although excess risk was smaller (OR, 2.4; 95% CI, 1.4-3.6).

Conclusions  Depot medroxyprogesterone contraception was associated with a greater risk of diabetes compared with combination oral contraceptive use only. Risk was associated with length of use and persisted after adjustment for body mass index. Additional research is needed for confirmation, but this risk should be considered in contraceptive choice for women at high risk for diabetes.

From the Robert Wood Johnson Clinical Scholars Program (Dr Kim) and Department of Medicine (Dr Kwok), University of Washington, Seattle; and Crownpoint Healthcare Facility, Crownpoint, NM (Drs Seidel and Begier).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(14):1783-1784.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Contraception After Gestational Diabetes
Damm et al.
Diabetes Care 2007;30:S236-S241.
FULL TEXT  

Long-acting injectable progestin contraception and risk of type 2 diabetes in latino women with prior gestational diabetes mellitus.
Xiang et al.
Diabetes Care 2006;29:613-617.
ABSTRACT | FULL TEXT  

Decline in Lung Function in Patients With Lymphangioleiomyomatosis Treated With or Without Progesterone
Taveira-DaSilva et al.
Chest 2004;126:1867-1874.
ABSTRACT | FULL TEXT  

Effects of Injectable or Implantable Progestin-Only Contraceptives on Insulin-Glucose Metabolism and Diabetes Risk
Kahn et al.
Diabetes Care 2003;26:216-225.
ABSTRACT | FULL TEXT